TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B‐Cell Lymphoma in the Real‐Life Patient Journey
Hematological Oncology · 2026-01 · 44 (1)
DOI: 10.1002/hon.70167 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Hematological Oncology, online erschienen am 14.01.2026. Verfasst von Lisa Argnani und 34 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Alma Mater Studiorum Università of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Lenalidomide, Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
The combination of tafasitamab and lenalidomide (tafa‐lena) has demonstrated efficacy in relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL), as evidenced by the L‐MIND study. To investigate the therapeutic potential and safety profile of tafa‐lena in real‐life, we conducted a national multicentric retrospective study. Eighty‐three patients with median age of 74 years were enrolled. The 49.4% of patients had a disease refractory to the first line therapy while 63.9% were refractory to the most recent one. The best overall response rate was 47% (28.9% complete remission). With a median follow‐up of 16 months, the median overall survival (OS) was 8.6 months and the median progression‐free survival (PFS) was 4.5 months. Disease‐free survival and median duration of response were reached at 52.8 and at 52.1 months, respectively. Compared to refractory disease ( N = 53, 63.9%), relapsed disease ( N = 26, 31.3%) was associated with better outcome in term of PFS (median 2.8 vs. 12.4 months) and OS (median 5.4 months vs. not reached). Neutropenia (52.5%) was the most common adverse events, predominantly related to lenalidomide. Our findings align with other real‐world studies, supporting the regimen as effective and safe, and highlighting that one third of patients experiencing long‐lasting responses even with dose reduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Alma Mater Studiorum Università of Bologna, Bologna, Italy.
- IRCCS IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
- UOS DH Ematologico Area Ematologia Trapianto Cellule Staminali Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy.
- Lymphoma Unit Hematology and Bone Marrow Transplantation Unit Department of OncoHematology IRCCS San Raffaele Scientific Institute, Milano, Italy.
- A.O. Citta della Salute e della Scienza, Torino, Italy.
- Ospedale Policlinico San Martino-IRCCS, Genova, Italy.
ORCID-Profile: Lisa Argnani, Ombretta Annibali, Enrico Derenzini, Valerio Guarente
Förderung
- Ministero della Salute
Zitieren
APA
Argnani, L., Pellegrini, C., Annibali, O., Angelillo, P., Amaducci, E., Ballerini, F., Bellisario, F., Bernardelli, A., Bruna, R., Califano, C., Cetani, G., Daghia, G., Derenzini, E., Frolli, A., Gaudio, F., Guarente, V., Gorgone, A., Valentina, L. E., Lucchini, E., …, & Zinzani, P. L. (2026). TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B‐Cell Lymphoma in the Real‐Life Patient Journey. Hematological Oncology, 44(1). https://doi.org/10.1002/hon.70167
Vancouver
Argnani L, Pellegrini C, Annibali O, Angelillo P, Amaducci E, Ballerini F, et al. TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B‐Cell Lymphoma in the Real‐Life Patient Journey. Hematological Oncology. 2026;44(1). doi:10.1002/hon.70167
BibTeX
@article{Argnani2026,
author = {Argnani, Lisa and Pellegrini, Cinzia and Annibali, Ombretta and Angelillo, Piera and Amaducci, Enrico and Ballerini, Filippo and Bellisario, Flaminia and Bernardelli, Andrea and Bruna, Riccardo and Califano, Catello and Cetani, Giusy and Daghia, Giulia and Derenzini, Enrico and Frolli, Antonio and Gaudio, Francesco and Guarente, Valerio and Gorgone, Ausilia and Valentina, Liardo Eliana and Lucchini, Elisa and Marino, Dario and Nassi, Luca and Nicoli, Paolo and Novo, Mattia and Palombi, Francesca and Patti, Caterina and Pavone, Vincenzo and Riva, Marcello and Russo, Filomena and Scapinello, Greta and Severino, Alessandro and Tani, Monica and Vallisa, Daniele and Casadei, Beatrice and Broccoli, Alessandro and Zinzani, Pier Luigi},
title = {TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B‐Cell Lymphoma in the Real‐Life Patient Journey},
journal = {Hematological Oncology},
year = {2026},
volume = {44},
number = {1},
doi = {10.1002/hon.70167}
}
EUVIMED